Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.

Cancer immunology, immunotherapy : CII - 1 Jan 2021

Ichihara Eiki, Harada Daijiro, Inoue Koji, Shibayama Takuo, Hosokawa Shinobu, Kishino Daizo, Harita Shingo, Ochi Nobuaki, Oda Naohiro, Hara Naofumi, Hotta Katsuyuki, Maeda Yoshinobu, Kiura Katsuyuki

Abstract excerpt

OBJECTIVES: Immune checkpoint inhibitors (ICIs) are less effective in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, a small percentage of patients with EGFR-mutant NSCLC do respond, and the characteristics of these patients are not known. Here, we identify the characteristics of patients who may respond to ICI therapy for EGFR-mutant NSCLC. PATIENTS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Immune Checkpoint Inhibitors

Share to Lung Neoplasms

Share to Progression-Free Survival

Share to Proportional Hazards Models

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32648165
DOI: 10.1007/s00262-020-02662-0
PMCID: PMC10991645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.PMID 32648165Read ↗

Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study.Semantic proximity Read ↗

Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer.Semantic proximity Read ↗

Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.Semantic proximity Read ↗

Persist or resist: Immune checkpoint inhibitors in EGFR ‐mutated NSCLCSemantic proximity Read ↗

The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation.Semantic proximity Read ↗

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancerSemantic proximity Read ↗

Efficacy and safety of immune checkpoint inhibitors in post-TKI NSCLC patients harboring EGFR mutations.Semantic proximity Read ↗

The efficacy and safety of immune checkpoint inhibitors for patients with EGFR-mutated non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy: A systematic review and network meta-analysis.Semantic proximity Read ↗

It is too Early to Say NO IMMUNOTHERAPY for EGFR‐Mutant NSCLC PatientsSemantic proximity Read ↗

Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Immunotherapy in advanced non-small-cell lung cancer with EGFR mutations.Semantic proximity Read ↗

Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.